You are here: Industry Insights > Dementia

News List

1 in 20 Cases of Dementia Occurs in People Under 65 drugs
July 22, 2021
Dementia is largely a disease of old age, but a new study finds that up to 5% of all cases are among people in the prime of their lives.
AHA News: Smoking Harms the Brain, Raises Dementia Risk – But Not If You Quit drugs
July 07, 2021
Everyone knows smoking is bad for the heart and lungs. But the damage it does to the brain often gets less attention than it should – from smokers and health care providers alike.
One-Third of Elderly Caregivers From Gray Market drugs
June 30, 2021
Gray market care represents a substantial proportion of paid, long-term care for older adults, according to a study published online June 11 in the Journal of Applied Gerontology.
Athira Pharma COO, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company firstwordpharma
June 18, 2021
Athira Pharma, Inc. today announced that Mark Litton, PhD, MBA, in his capacity as Chief Operating Officer, has assumed day-to-day leadership responsibilities for the Company, effective immediately.
Study identifies how COVID-19 linked to Alzheimer's disease-like cognitive impairment worldpharmanews
June 16, 2021
A new Cleveland Clinic-led study has identified mechanisms by which COVID-19 can lead to Alzheimer's disease-like dementia. The findings, published in Alzheimer's Research & Therapy, indicate an overlap between COVID-19 and brain changes common in ...
Could a Type of Statin Raise Dementia Risks? drugs
June 16, 2021
Certain cholesterol-lowering drugs might speed dementia in some older adults whose memories are starting to fail, a small, preliminary study suggests.
FDA Approves Aducanumab To Treat Alzheimer’s Disease contractpharma
June 09, 2021
The U.S. Food and Drug Administration (FDA) has approved aducanumab, the first drug that slows Alzheimer's disease. Aducanumab is also the first novel therapy for Alzheimer’s disease approved since 2003.
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia americanpharmaceuticalreview
April 09, 2021
Acadia Pharmaceuticals Inc. announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment ...
Noncommunicable diseases are leading cause of death and disability worldwide, says WHO europeanpharmaceuticalreview
December 11, 2020
Alzheimer’s and diabetes enter the top ten global causes of death for the first time, while HIV/AIDS and tuberculosis deaths fall, according to the WHO’s 2019 Global Health Estimates.
Eisai and Wren Therapeutics to collaborate for drug discovery for synucleinopathies expresspharma
December 01, 2020
This collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of α-synuclein misfolding and aggregation.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page